series-b
Stage
2020
Founded
1
Investors
About
SynOx Therapeutics is a clinical-stage company developing emactuzumab, a next-generation monoclonal antibody targeting CSF-1R to treat tenosynovial giant cell tumours (TGCT) and other macrophage-driven diseases.
Explore SynOx Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.